EMA grants PRIME designation to DNX-2401

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The European Medicines Agency granted a PRIority MEdicines, or PRIME, designation for DNX-2401 as a treatment for recurrent glioblastoma. The PRIME designation was launched by the EMA in March to accelerate the regulatory approval of breakthrough therapies that target an unmet medical need. The objective is to provide patients who have few treatment options with...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login